Search research articles
Contact Us
Filters
Showing results (71-80 of 143) with videos related to
Page
of 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
Lesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors
Mrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, et al.
Pediatric Blood & Cancer
|
October 2, 2012
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors
Margaret E Macy, Tracey Duncan, James Whitlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)
Holly A Massett, Grace Mishkin, Jeffrey A Moscow, et al.
Lancet (London, England)
|
August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials
Dai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
Dai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Elisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Frontiers in Medicine
|
June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials
Channing J Paller, Erich P Huang, Thomas Luechtefeld, et al.
Investigational New Drugs
|
January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
Srikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group
R Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.
Page
of 15
Search research articles
Search
Showing results (71-80 of 143) with videos related to
Sort By:
Page
of 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee
Lesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors
Mrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, et al.
Pediatric Blood & Cancer
|
October 2, 2012
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors
Margaret E Macy, Tracey Duncan, James Whitlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)
Holly A Massett, Grace Mishkin, Jeffrey A Moscow, et al.
Lancet (London, England)
|
August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials
Dai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
Dai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Elisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Frontiers in Medicine
|
June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials
Channing J Paller, Erich P Huang, Thomas Luechtefeld, et al.
Investigational New Drugs
|
January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
Srikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group
R Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.
Page
of 15